A recent article by Ghosh et al. entitled "Optimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairments in rats" provides an important new set of information on neuroinflammation and cognitive deficit in a rat model of sporadic Alzheimer's disease (sAD) based on intracerebroventricular administration of streptozotocin (STZ-icv) in Charles-Foster rats in the early post-treatment period of 21 days. This comment is supposed to supplement the aforementioned manuscript by providing additional perspective on important factors that should be taken into account in the process of optimization of the streptozotocin (STZ) dose for intracerebroventricular treatment, and provides a brief overview of possible sources of variation of experimental results reported by different groups working with STZ-icv rodent models.

Ghosh等人的最新文章。题为“优化脑室内链脲佐菌素剂量以诱导大鼠神经炎症和记忆障碍”，在基于脑室内链脲佐菌素给药（STZ- icv）在21天的早期治疗后的Charles-Foster大鼠中。本评论应通过提供对重要因素的补充观点来补充上述手稿，这些重要因素应在优化链脲佐菌素（STZ）剂量以进行脑室内治疗的过程中予以考虑，